Core Insights - Transgene is advancing its individualized neoantigen therapeutic vaccine, TG4050, which has shown durable clinical outcomes in head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapse [1][4][6] - The company has sufficient financial resources to support its operations until early 2028, following a successful fundraising of approximately €105 million and the conversion of €39 million debt into shares [21][26] - The randomized Phase 2 part of the clinical trial for TG4050 is nearing completion, with the primary endpoint being two-year disease-free survival [10][11] Clinical Development - TG4050 has demonstrated a 100% disease-free survival rate after more than two years of follow-up in the Phase 1 trial, meeting all trial endpoints [7][8] - A new Phase 1 trial for a second indication in operable solid tumors is planned to start in 2026, reflecting the strategy to expand the clinical evaluation of the myvac® platform [2][12] - Positive results from the Phase 1 trial of BT-001 support further clinical development, showing antitumoral activity in patients with advanced refractory tumors [15][17] Financial Performance - Operating revenue for 2025 was €7.2 million, an increase from €6.4 million in 2024, primarily driven by research tax credits [22][43] - The company reported a net loss of €37.5 million in 2025, compared to a net loss of €34.0 million in 2024, with a net cash burn of €38.2 million [26][48][50] - Cash, cash equivalents, and other financial assets totaled €111.9 million as of December 31, 2025, significantly up from €16.7 million at the end of 2024 [26][49] Strategic Initiatives - Transgene is optimizing its manufacturing processes to prepare for potential pivotal clinical trials [13] - The company is leveraging its proprietary VacDesignR® computational tool to enhance the quality and reliability of its vaccine production [14] - Recent leadership additions aim to accelerate the development of the myvac® platform, with new appointments in key executive roles [19][20]

Core Insights - Transgene is set to present its proprietary computational tool, VacDesignR®, at the ESMO AI & Digital Oncology 2025 conference, which enhances the design and production of recombinant Modified Vaccinia Ankara (MVA)-based vectors for individualized neoantigen therapeutic vaccines [1][2][5] Group 1: VacDesignR® Tool - VacDesignR® optimizes recombinant plasmid architecture for MVA vectors, improving production reliability and vector quality by minimizing unwanted homologous recombination and intelligently selecting peptide sequences [3] - Future versions of VacDesignR® will integrate AI components to enhance performance and scalability, aligning with Transgene's strategy to expedite production timelines for individualized therapeutic vaccines [4] Group 2: Clinical Development - The individualized immunotherapies developed through the myvac® platform are currently in a Phase I/II clinical trial (NCT04183166), utilizing the VacDesignR® tool for their design [2] - TG4050, the first individualized therapeutic vaccine based on the myvac® platform, is designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy [4][8] Group 3: Company Overview - Transgene focuses on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [8] - The myvac® platform allows for the creation of personalized immunotherapies that encode patient-specific mutations, utilizing advanced AI technologies [9]